Skip to main content
NCBI home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2006 May 23;20(3):93–97. doi: 10.1002/jcla.20107

Association between the TAP2 gene codon 665 polymorphism and Graves' Disease

Rong‐Hsing Chen 1, Tze‐Yuan Wang 1, Wen‐Chi Chen 2,3, Chang‐Hai Tsai 4,5, Fuu‐Jen Tsai 3,4,✉
PMCID: PMC6807603  PMID: 16721835

Abstract

A total of 95 patients with active Graves' disease (GD) and 105 normal healthy subjects were enrolled in this study, which attempted to determine whether single‐site polymorphisms of the transporter associated with antigen processing 2 (TAP2) gene contribute to an individual's susceptibility to GD. Such polymorphisms were detected using polymerase chain reaction (PCR)‐based restriction analysis. Associations between GD and the three site polymorphisms of the TAP2 gene at codons 379, 565, and 665 were investigated. The results of the genotype analysis revealed that the frequency of the GG homozygote's presence at codon 665 was lower, and that of the AA homozygote's presence was greater in GD patients (15.8% and 36.8%, respectively) compared to normal controls (34.3% and 16.2%, respectively; P<0.001). The OR (OD) for the risk of occurrence for the AA homozygote and AG heterozygote compared to the GG homozygote (as was the case for the GD patients) was respectively 4.941 and 2.117, with respective 95% confidence intervals (CI) of 2.303–10.598 and 1.020–4.369. The allelic analysis also demonstrated reduced G and enhanced A allele frequencies for GD patients compared to controls (respectively 39.5% vs. 59.0% [G allele], and 60.5% vs. 41.0% [A allele]; P=0.0001; OR=2.219, 95% CI: 1.449–3.395). By contrast, the differences between patient and control groups for the frequency of appearance of genotypes and allelic variants at codon 379 (P=0.522 and P=0.306, respectively) and codon 565 (P=0.199 and P=0.157, respectively) did not appear to be significant. These data reveal that the single‐site polymorphism of the TAP2 gene at codon 665 may be an indicator for predicting GD development. J. Clin. Lab. Anal. 20:93–97, 2006. © 2006 Wiley‐Liss, Inc.

Keywords: codon, Graves' disease, polymorphism, transporter associated with antigen processing

REFERENCES

  • 1. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997; 84:223–243. [DOI] [PubMed] [Google Scholar]
  • 2. Larsen PR, Alexander NM, Chopra IJ, et al. Revised nomenclature for tests of thyroid hormones and thyroid‐related proteins in serum. J Clin Endocrinol Metab 1987; 64:1089–1094. [DOI] [PubMed] [Google Scholar]
  • 3. Bottazzo GF, Pujol‐Borrell R, Hanafusa T, Feldmann M. Role of aberrant HLA‐DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet 1983; 2:1115–1119. [DOI] [PubMed] [Google Scholar]
  • 4. Momburg F, Neefjes JJ, Hammerling GJ. Peptide selection by MHC‐encoded TAP transporters. Curr Opin Immunol 1994; 6:32–37. [DOI] [PubMed] [Google Scholar]
  • 5. Trowsdale J, Hanson I, Mockridge I, Beck S, Townsend A, Kelly A. Sequences encoded in the class II region of the MHC related to the “ABC” superfamily of transporters. Nature 1990; 348:741–744. [DOI] [PubMed] [Google Scholar]
  • 6. Ma L, Penfornis A, Wang X, et al. Evaluation of TAP1 polymorphisms with insulin dependent diabetes mellitus in Finnish diabetes patients. The Childhood Diabetes in Finland (DiMe) Study Group. Hum Immunol 1997; 53:159–166. [DOI] [PubMed] [Google Scholar]
  • 7. Singal DP, Ye M, Qiu X, D'Souza M. Polymorphisms in TAP2 genegene and their association with rheumatoid arthritis. Clin Exp Rheumatol 1994; 12:29–33. [PubMed] [Google Scholar]
  • 8. Middleton D, Megaw G, Cullen C, Hawkins S, Darke C, Savage DA. TAP1 and TAP2 polymorphism in multiple sclerosis patients. Hum Immunol 1994; 40:131–134. [DOI] [PubMed] [Google Scholar]
  • 9. Barron KS, Reveille JD, Carrington M, Mann DL, Robinson MA. Susceptibility to Reiter's syndrome is associated with alleles of TAP genes. Arthritis Rheumatism 1995; 38:684–698. [DOI] [PubMed] [Google Scholar]
  • 10. Rau H, Nicolay A, Usadel KH, et al. Polymorphisms of TAP1 and TAP2 genes in Graves' disease. Tissue Antigens 1997; 49:16–22. [DOI] [PubMed] [Google Scholar]
  • 11. Ofosu MH, Brown C, Cheatham W, Henry L, Austin C. TAP1 polymorphism identified in African‐American Graves' disease patients. Immunol Invest 1998; 27:281–289. [DOI] [PubMed] [Google Scholar]
  • 12. Cai M, Yan L, Cheng H, Ding H, Fu Z. Antigen transporter gene polymorphism and predisposition to Graves' disease: a preliminary analysis. Zhonghua Nei Ke Za Zhi 2002; 41:758–761. [PubMed] [Google Scholar]
  • 13. Chen RH, Chen WC, Chen CC, Tsai CH, Tsai FJ. Association between the TAP1 gene codon 637 polymorphism and Graves' disease. Endocrine 2004; 25:137–140. [DOI] [PubMed] [Google Scholar]
  • 14. Kuwata S, Yanagisawa M, Saeki H, et al. Lack of primary association between transporter associated with antigen processing genes and atopic dermatitis. J Allergy Clin Immunol 1995; 94:565–574. [DOI] [PubMed] [Google Scholar]
  • 15. Takeuchi F, Nakano K, Nabeta H, Hong GH, Kuwata S, Ito K. Polymorphisms of the TAP1 and TAP2 transporter genes in Japanese SLE. Ann Rheum Dis 1996; 55:924–926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Ismail A, Bousaffara R, Kaziz J, et al. Polymorphism in transporter antigen peptides gene (TAP1) associated with atopy in Tunisians. J Allergy Clin Immunol 1997; 99:216–223. [DOI] [PubMed] [Google Scholar]
  • 17. Colonna M, Bresnahan M, Bahram S, Strominger JL, Spies T. Allelic variants of the human putative peptide transporter involved in antigen processing. Proc Natl Acad Sci USA 1992; 89:3932–3936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Chen HL, Gabrilovich D, Tampe R, Girgis KR, Nadaf S, Carbone DP. A functional defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet 1996; 13:210–213. [DOI] [PubMed] [Google Scholar]
  • 19. van Endert PM, Lopez MT, Patel SD, Monaco JJ, McDevitt HO. Genomic polymorphism, recombination, and linkage disequilibrium in human major histocompatibility complex‐encoded antigen‐processing genes. Proc Natl Acad Sci USA 1992; 89:11594–11597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Carrington M, Colonna M, Spies T, Stephens JC, Mann DL. Haplotypic variation of the transporter associated with antigen processing (TAP) genes and their extension of HLA class II region haplotypes. Immunogenetics 1993; 37:266–273. [DOI] [PubMed] [Google Scholar]
  • 21. Bene MC, Derennes V, Faure G, Thomas JL, Duheille J, Leclere J. Graves' disease: in situ localization of lymphoid T cell subpopulations. Clin Exp Immunol 1983; 52:311–316. [PMC free article] [PubMed] [Google Scholar]
  • 22. Warford A, McLachlan SM, Malcolm AJ, Young ET, Farndon JR, Rees Smith B. Characterization of lymphoid cells in the thyroid of patients with Graves' disease. Clin Exp Immunol 1984; 57:626–632. [PMC free article] [PubMed] [Google Scholar]
  • 23. Misaki T, Konishi J, Nakashima T, et al. Immunohistological phenotyping of thyroid infiltrating lymphocytes in Graves' disease and Hashimoto's thyroiditis. Clin Exp Immunol 1985; 60:104–110. [PMC free article] [PubMed] [Google Scholar]
  • 24. Malnati MS, Marti M, LaVaute T, et al. Processing pathways for presentation of cytosolic antigen to MHC class II‐ restricted T cells. Nature 1992; 357:702–704. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES